Clinical and economic issues in adjuvant chemotherapy for HER-2 positive breast cancer;Aspectos clínico-econômicos da quimioterapia adjuvante no câncer de mama HER-2 positivo

Revista da Associacao Medica Brasileira

Volumn 54, Issue 6, 2008, Pages 494-499

  Martins, Sandro José ^a,b   Yamamoto, Crystina Aoki ^a  

^a Instituto Médico Legal Nina Rodrigues   (Brazil)

^b NONE

Author keywords

Adjuvant chemotherapy; Breast cancer; Cost efficiency analysis; Health expenditures; Supplemental health; Trastuzumab

Indexed keywords

EID: 60149101404     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302008000600012     Document Type: Article

References (23)

1. Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, et al. NCCN Task Force Report: adjuvant therapy for breast cancer. J Natl Compr Cancer Netw. 2006;4(Suppl 1):S1-26.
2. Piccart-Gebhart MJ. Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn. Eur J Cancer. 2006;42:1715-9.
3. Viani GA, Afonso SL, Stefano EJ, De Fendi LI ,Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.
4. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809-20.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-72.
6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-84.
7. Robert NJ, Eiermann W, Pienkowski T, Crown J, Martin M, Pawlicki M, et al. BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of life (QOL) at 36 months follow-up. ASCO Annual Meeting. 2007. p.1964-7.
8. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-36.
9. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000;18:3302-17.
10. Altman DG ,Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319:1492-5.
11. Sanitária CdRdMdM-ANdV. Listas de preços máximos de medicamentos ao consumidor; 2007 [citado dez 2007]. Available from: http://www.anvisa.gov.br/monitora/precos.htm.
12. Sharp SJ, Thompson SG ,Altman DG. The relation between treatment benefit and underlying risk in meta-analysis. BMJ. 1996;313:735-8.
13. Saúde. INdC-Md. Estimativa 2006: incidência de câncer no Brasil[citado dez 2007]. Available from: http://www.inca.gov.br/estimativa/ 2006.
14. Barrett A, Roques T, Small M ,Smith RD. How much will Herceptin really cost? BMJ. 2006;333:1118-20.
15. Hillner BE ,Smith TJ. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? J Clin Oncol. 2007;25:611-3.
16. Norum J. The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer. Expert Opin Pharmacother. 2006;7:1617-25.
17. De Moraes AB, Zanini RR, Turchiello MS, Riboldi J ,De Medeiros LR. Estudo da sobrevida de pacientes com câncer de mama atendidas no hospital da Universidade Federal de Santa Maria, Rio Grande do Sul, Brasil. Cad Saude Publica. 2006; 22:2219-28.
18. Koch H, Peixoto J ,Eiras A. Análise da infra-estrutura para a mamografia no Brasil. Radiol Bras. 2000;33:23-30.
19. Mendonca GA, Silva AM ,Caula WM. Características tumorais e sobrevida de cinco anos em pacientes com câncer de mama admitidas no Instituto Nacional de Câncer, Rio de Janeiro, Brasil. Cad Saude Publica. 2004;20:1232-9.
20. Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R ,Garber AM. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007;25:634-41.
21. Liberato NL, Marchetti M ,Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007;25:625-33.
22. Garcia-Saenz JA, Martin M, Puente J, Lopez-Tarruella S, Casado A, Moreno F, et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer. 2005;6:325-9.
23. Pusztai L ,Esteva FJ. Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Invest. 2006;24:187-91.